Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01708993
Title Reolysin in Patients With Previously Treated Advanced or Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors NCIC Clinical Trials Group|Oncolytics Biotech
Indications

lung non-small cell carcinoma

Therapies

Docetaxel

Pemetrexed Disodium

Pelareorep + Pemetrexed Disodium

Docetaxel + Pelareorep

Age Groups: adult
Covered Countries CAN

Facility Status City State Zip Country Details
Tom Baker Cancer Centre Calgary Alberta T2N 4N2 Canada Details
BCCA - Abbotsford Centre Abbotsford British Columbia V2S 0C2 Canada Details
BCCA - Fraser Valley Cancer Centre Surrey British Columbia V3V 1Z2 Canada Details
BCCA - Vancouver Cancer Centre Vancouver British Columbia V5Z 4E6 Canada Details
Juravinski Cancer Centre at Hamilton Health Sciences Hamilton Ontario L8V 5C2 Canada Details
Cancer Centre of Southeastern Ontario at Kingston Kingston Ontario K7L 5P9 Canada Details
London Regional Cancer Program London Ontario N6A 4L6 Canada Details
Lakeridge Health Oshawa Oshawa Ontario L1G 2B9 Canada Details
Ottawa Hospital Research Institute Ottawa Ontario K1H 8L6 Canada Details
Univ. Health Network-Princess Margaret Hospital Toronto Ontario M5G 2M9 Canada Details
CHUM - Hopital Notre-Dame Montreal Quebec H2L 4M1 Canada Details
Allan Blair Cancer Centre Regina Saskatchewan S4T 7T1 Canada Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field